proteasome inhibitors
3 abstracts
Abstract
CAMMA 2: A phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent.Org: Mayo Clinic, Sarah Cannon Transplant and Cellular Therapy Program, Genentech, F. Hoffmann-La Roche Ltd,
Abstract
Treatment patterns of triple-class refractory (TCR) multiple myeloma (MM) across the United States (US), Canada, and western Europe: A real-world observational chart review study.Org: RTI Health Solutions, Pfizer Inc., London, United Kingdom,
Abstract
Clinical outcomes and national information of patients with multiple myeloma (MM) covered under the largest national health insurance in a low-middle-income country.Org: Centro Integral de Cancer-Clinica de Occidente, nueva eps, Clinica De Occidente, NALT MEDICAL SOLUTIONS,